These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 18956950)

  • 21. A review of the development of Respimat Soft Mist Inhaler.
    Dalby R; Spallek M; Voshaar T
    Int J Pharm; 2004 Sep; 283(1-2):1-9. PubMed ID: 15363496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hood nebulization: effects of head direction and breathing mode on particle inhalability and deposition in a 7-month-old infant model.
    Kim J; Xi J; Si X; Berlinski A; Su WC
    J Aerosol Med Pulm Drug Deliv; 2014 Jun; 27(3):209-18. PubMed ID: 23808762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An in vitro study to assess facial and ocular deposition from Respimat Soft Mist inhaler.
    Newman SP; Steed KP; Reader SJ; Pavia D; Sohal AK
    J Aerosol Med; 2007; 20(1):7-12. PubMed ID: 17388748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deposition of Particles in Human Mouth-Throat Replicas and a USP Induction Port.
    Cheng YS; Zhou Y; Su WC
    J Aerosol Med Pulm Drug Deliv; 2015 Jun; 28(3):147-55. PubMed ID: 25137223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metered dose inhaler aerosol deposition in a model of the human respiratory system and a comparison with clinical deposition studies.
    Velasquez DJ; Gabrio B
    J Aerosol Med; 1998; 11 Suppl 1():S23-8. PubMed ID: 10180729
    [No Abstract]   [Full Text] [Related]  

  • 26. A dry powder inhaler with reduced mouth-throat deposition.
    Wang ZL; Grgic B; Finlay WH
    J Aerosol Med; 2006; 19(2):168-74. PubMed ID: 16796541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Bio-relevant Mouth-Throat Models for Characterization of Metered Dose Inhalers.
    Kaviratna A; Tian G; Liu X; Delvadia R; Lee S; Guo C
    AAPS PharmSciTech; 2019 Feb; 20(3):130. PubMed ID: 30815748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Pressurized Metered Dose Inhaler Spray Characteristics and Particle Size Distribution on Drug Delivery Efficiency.
    Yousefi M; Inthavong K; Tu J
    J Aerosol Med Pulm Drug Deliv; 2017 Oct; 30(5):359-372. PubMed ID: 28463041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-Efficiency Nose-to-Lung Aerosol Delivery in an Infant: Development of a Validated Computational Fluid Dynamics Method.
    Bass K; Boc S; Hindle M; Dodson K; Longest W
    J Aerosol Med Pulm Drug Deliv; 2019 Jun; 32(3):132-148. PubMed ID: 30556777
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of Nasal Inhalation on Drug Particle Deposition and Size Distribution in the Upper Airway: With Soft Mist Inhalers.
    Sadeghi T; Fatehi P; Pakzad L
    Ann Biomed Eng; 2024 May; 52(5):1195-1212. PubMed ID: 38509413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intermittent aerosol delivery to the lungs during high-flow nasal cannula therapy.
    Golshahi L; Longest PW; Azimi M; Syed A; Hindle M
    Respir Care; 2014 Oct; 59(10):1476-86. PubMed ID: 24917454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing the in vitro performance of Respimat.
    Zierenberg B
    J Aerosol Med; 1999; 12 Suppl 1():S19-24. PubMed ID: 10623337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dry powder inhaler aerosol deposition in a model of tracheobronchial airways: Validating CFD predictions with in vitro data.
    Ahookhosh K; Saidi M; Aminfar H; Mohammadpourfard M; Hamishehkar H; Yaqoubi S
    Int J Pharm; 2020 Sep; 587():119599. PubMed ID: 32663586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding the effects of inhaler resistance on particle deposition behaviour - A computational modelling study.
    Cai X; Dong J; Milton-McGurk L; Lee A; Shen Z; Chan HK; Kourmatzis A; Cheng S
    Comput Biol Med; 2023 Dec; 167():107673. PubMed ID: 37956626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coupled in silico platform: Computational fluid dynamics (CFD) and physiologically-based pharmacokinetic (PBPK) modelling.
    Vulović A; Šušteršič T; Cvijić S; Ibrić S; Filipović N
    Eur J Pharm Sci; 2018 Feb; 113():171-184. PubMed ID: 29054499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validating Whole-Airway CFD Predictions of DPI Aerosol Deposition at Multiple Flow Rates.
    Longest PW; Tian G; Khajeh-Hosseini-Dalasm N; Hindle M
    J Aerosol Med Pulm Drug Deliv; 2016 Dec; 29(6):461-481. PubMed ID: 27082824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Respimat®, first Soft Mist™ inhaler: new perspectives in the management of COPD].
    Henriet AC; Marchand-Adam S; Mankikian J; Diot P
    Rev Mal Respir; 2010 Dec; 27(10):1141-9. PubMed ID: 21163393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro aerosol deposition in the oropharyngeal region for Staccato loxapine.
    Dinh KV; Myers DJ; Noymer PD; Cassella JV
    J Aerosol Med Pulm Drug Deliv; 2010 Aug; 23(4):253-60. PubMed ID: 20528148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aerosol Therapy in Adults Receiving High Flow Nasal Cannula Oxygen Therapy.
    Réminiac F; Vecellio L; Heuzé-Vourc'h N; Petitcollin A; Respaud R; Cabrera M; Pennec DL; Diot P; Ehrmann S
    J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):134-41. PubMed ID: 26196740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI.
    Zuwallack R; De Salvo MC; Kaelin T; Bateman ED; Park CS; Abrahams R; Fakih F; Sachs P; Pudi K; Zhao Y; Wood CC;
    Respir Med; 2010 Aug; 104(8):1179-88. PubMed ID: 20172704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.